Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond

Figure 2 Possible sequential therapies of molecular targeted agents for hepatocellular carcinoma in the real-world practice[53]. There are solid evidence for use of regorafenib, ramucirumab, cabozantinib after sorafenib as confirmed by RESORCE, REACH-2 and CERESTIAL trials. However, lenvatinib has been proven to be effective after sorafenib or regorafenib in the real world practice as a second-line or third-line agent. Effectiveness of second-line agents after lenvatinib failure should be explored in the real-world practice setting. AFP: Alphafeto protein.